Bangladeshi scientist discover new medicine of Dengue fever !
Bangladeshi scientists have found effectiveness of eltrombopag medicine to correct thrombocytopaenia in moderate to severe dengue patients.
A total of 101 patients including 77 DF and 24 DHF patients completed the trial as eight patients left the trial without completing the follow-up. Medical journal Lancet published the research on its website November 21.
Twelve scientists Sajib Chakrabarty, Sarwar Alam, Mohammad Sayem, Mousumi Sanyal, Tonmoy Das,Piyal Saha,Mohammad Sayem, Bartholomia Keya Bepari, Chowdhury Tamanna Tabassum, Ahmedul Kabir, Md.Robed Amin and A.H.M. Nurun Nabi have conducted the trial and research of the medicine.
In this open-label, randomized controlled phase-II trial, patients with dengue fever (DF) and dengue hemorrhagic fever (DHF) having platelet (PLT) count lower than 100 × 109/L without comorbidity, pregnancy, and liver abnormalities were enrolled in Dhaka Medical College Hospital, Better Life Hospital and AMZ hospital, Dhaka, Bangladesh. Between October 10, 2019, and December 30, 2019, 123 DF and DHF patients were assessed for eligibility to be enrolled in the trial.
Two doses of eltrombopag – 25 mg/day and 50 mg/day were administered to Group-1 and Group-2 patients, respectively whereas the control-group patients received standard dengue treatment without eltrombopag. The management of all enrolled patients was according to WHO guidelines. The randomization procedure was performed by using a computerized system (STATA Inc.), according to Lancet.
The trial hints toward the positive effect of eltrombopag in the cessation of bleeding manifestation. Administration of the lower dose (25 mg/day) of eltrombopag was shown to be safer and equally efficacious to the higher dose (50 mg/day) in treating dengue-infected patients.
